AI for medical affairs in biopharma
Medical affairs is a relationship business run under rules that make most software useless for the interesting half. What is left, once you take out everything that has to be reviewed, is a coordination problem, and that is the part this addresses.
The exclusions are large enough that they belong before anything else. This does not review content. It has no part in medical, legal and regulatory approval of any material, and nothing it drafts is approved content. It does not handle adverse event capture or safety reporting, it is not a validated system, it keeps no controlled record, and it does not touch patient identifiable information. If any of those is the job, buy something built and qualified for it.
One consequence deserves its own sentence. A field medical conversation can surface something reportable, and if it does, the obligation to route that into your safety process on your own timelines is entirely yours and entirely outside this system. That same boundary, stated for the organization as a whole, is on AI agents for pharma.
What medical affairs actually loses
Not content. Content is the part that has a process, a queue and an owner. What has no process is the relationship state: the running record of who said what, to whom, and what somebody undertook to do about it.
- An investigator asks at a congress for a paper you said you would send, and you said it in a corridor.
- An advisory board produces eleven recommendations, three of which someone was supposed to act on, and the deck that came out of it says none of that.
- A publication plan has an author who owes a draft, a journal with a submission window, and a co-author who has gone quiet for a month.
- An investigator initiated study proposal arrives, needs an internal answer, and sits for five weeks because nobody owns the clock on it.
- A key opinion leader you have met four times over two years asks something that assumes you remember the last conversation, and you do not.
Every one of those is an open loop with a person and a date attached, and in most teams they live in a calendar, an inbox and a memory. A field medical lead covering a therapeutic area alone can be carrying sixty of them.
What a coordination layer does with them
It reads the mail and the meeting transcripts you already generate, files each to the relationship or the project it belongs to, and keeps the record of what is open. It builds the history for each person you deal with as a side effect of correspondence rather than as data entry: what was discussed, what you committed to, what they committed to, and which projects the relationship touches. Before a meeting it assembles a brief from those threads so you walk in knowing the last four conversations without having reread them.
It watches your sent mail as well as your inbox, so a promise you made going out is tracked the same way as one made to you. Congress and event deadlines, submission windows and contract dates get a heads up scheduled before they come due rather than on the day. Every outbound message is drafted and queued for you to approve, edit or discard, and nothing is sent on its own.
The rule that keeps this on the safe side of the line. Everything above is a record of your own working week: who you spoke to, what is open, what is due. None of it is a regulated record, none of it is approved content, and none of it substitutes for a process your company already runs. If a use you have in mind blurs those, that is a signal to route it to the qualified system rather than to stretch this one.
Scale, and who this is actually for
It is single seat. One install, for one person, on their own mail identity. A colleague's commitment shows up as a thing for you to check, never as a task assigned to them, and it will not message anyone on your team or any external contact without you approving the message. There is no shared workspace, no permissions model and no administrator console.
That makes the realistic buyer a person rather than a department: a medical affairs lead at a company small enough that they decide what runs on their own laptop, or one wearing the medical affairs hat alongside two others. At organizational scale the purchase runs into a vendor questionnaire and a security review that will cost more than the thing being bought, and the pharma CRM comparison is a more useful page for that situation.
The same argument in category terms is knowledge management in pharma. The version of this written for the regulatory function next door is AI tools for regulatory affairs, and the closest functional cousin, because the mechanics of relationship history are nearly identical, is AI for business development in biotech. Everything in this set is indexed at AI for life sciences.
The paper you promised in a corridor, still tracked
Advisory board actions, a co-author who has gone quiet on the publication, an investigator initiated proposal with nobody holding its clock, each kept against the person and the project it belongs to, with a brief drawn from those threads before you sit down with that key opinion leader again. Approved content and safety reporting stay in the systems that own them, and the demo covers the rest.
See the demo